WebNov 18, 2024 · Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will … WebSep 19, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 19, 2024-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic …
Dicerna Pharmaceuticals appoints Dr Steve Doberstein to its Board …
Web`unanimously approved by the Dicerna Board of Directors and the Board of `Directors of Novo Nordisk. . . . ` `Under the terms of the agreement, Novo Nordisk, through a subsidiary, will initiate `a tender offer to acquire all outstanding shares of Dicerna common stock at a price `of $38.25 per share in cash. WebDicerna Evolves Its Board of Directors to Support Continued Growth January 24, 2024 ... Ms. Protopapas has served on the board of directors of Ariad Pharmaceuticals from May 2015 to February 2024 when it was sold to Takeda for $5.2 billion . Ms. Protopapas also served on the board of Bioverativ from January 2024 to January 2024 when it was sold ... richard rivers md
Dicerna™ Appoints Patrick Gray to Board of Directors to ... - BioSpace
WebNov 18, 2024 · Novo Nordisk and Dicerna have been parties to a research collaboration since 2024 to discover and develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology. WebNov 18, 2024 · The transaction was unanimously approved by the Dicerna Board of Directors and the Board of Directors of Novo Nordisk. ... Dicerna’s RNAi technology platform enables access to intracellular ... WebSep 19, 2024 · Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the Dicerna board of directors (the “board”) as an independent director, and the retirement of veteran director Dennis Langer, M.D., J.D. … red maple chlorosis